Editorial
|
|
|
|
|
Why is it so difficult to put proven advances into practice?
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Inconclusive evaluation
|
|
|
|
|
|
|
|
|
|
|
|
Uncertain efficacy but real dangers
|
|
|
|
|
|
|
|
|
|
Prolongs survival by a few months, but highly toxic
|
|
|
|
|
|
|
|
|
|
Avoid in both men and women
|
|
|
|
|
|
|
|
|
|
No advantage over first-line clopidogrel
|
|
|
|
|
|
|
|
|
|
Cardiovascular reactions should be better documented
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
First-choice treatments
|
|
|
|
|
|
|
|
|
|
No reduction in mortality
|
|
|
|
|
|
|
|
|
|
Reduction in injurious falls
|
|
|
|
Outlook
|
|
|
|
|
A complex and little-evaluated tool
|
|
|
|
|
|
|
|